In melanoma, knockdown of the receptors or the use of antagonists or neutralizing antibodies against CXCR1/2 affected cell proliferation, migration and tumor growth, strongly indicating the involvement of these receptors in melanoma progression (34). The gene discussed is CXCR1; the disease is melanoma.